Wolfgang Oster Selected Research

TIC10 compound

12/2020	ONC201 and imipridones: Anti-cancer compounds with clinical efficacy.
11/2020	Biological activity of weekly ONC201 in adult recurrent glioblastoma patients.
10/2019	Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
4/2019	First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report.
1/2019	Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration.
1/2019	Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism.
1/2018	Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.
10/2017	Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP.
10/2017	A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma.
10/2017	Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Wolfgang Oster Research Topics

Disease

15	Neoplasms (Cancer) 12/2020 - 11/2016
4	Glioma (Gliomas) 12/2020 - 01/2019
4	Hematologic Neoplasms (Hematological Malignancy) 12/2020 - 11/2016
3	Glioblastoma (Glioblastoma Multiforme) 11/2020 - 10/2017
2	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 12/2020 - 01/2018
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2019 - 01/2018
2	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 01/2018 - 09/2017
2	Melanoma (Melanoma, Malignant) 10/2017 - 10/2017
1	Prostatic Neoplasms (Prostate Cancer) 12/2020
1	Endometrial Neoplasms (Endometrial Cancer) 12/2020
1	Diffuse Intrinsic Pontine Glioma 04/2019
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2018
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2018
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2018
1	Multiple Myeloma 01/2018
1	Leukemia 01/2018
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2018
1	Hodgkin Disease (Hodgkin's Disease) 01/2018
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2018
1	Sclerosis 01/2018
1	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 01/2018
1	Burkitt Lymphoma (Burkitt's Lymphoma) 01/2018
1	Liver Neoplasms (Liver Cancer) 10/2017
1	Pancreatic Neoplasms (Pancreatic Cancer) 10/2017
1	Skin Neoplasms (Skin Cancer) 10/2017
1	Breast Neoplasms (Breast Cancer) 01/2017
1	Triple Negative Breast Neoplasms 01/2017

Drug/Important Bio-Agent (IBA)

14	TIC10 compoundIBA 12/2020 - 11/2016
4	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 12/2019 - 10/2017
3	Dopamine Receptors (Dopamine Receptor)IBA 11/2020 - 01/2019
3	ONC212IBA 12/2019 - 10/2017
2	TNF-Related Apoptosis-Inducing Ligand ReceptorsIBA 12/2020 - 11/2020
2	Dexamethasone (Maxidex)FDA LinkGeneric 04/2019 - 01/2018
2	Bevacizumab (Avastin)FDA Link 04/2019 - 10/2017
2	Biomarkers (Surrogate Marker)IBA 01/2018 - 10/2017
1	dipinacoline glutamateIBA 10/2019
1	Histones (Histone)IBA 04/2019
1	Bortezomib (Velcade)FDA Link 01/2018
1	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2018
1	Fluorouracil (Carac)FDA LinkGeneric 10/2017
1	Endoplasmic Reticulum Chaperone BiPIBA 10/2017
1	CrizotinibIBA 10/2017
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 10/2017
1	Irinotecan (Camptosar)FDA LinkGeneric 10/2017
1	tyrphostin AG 1024IBA 10/2017
1	ProlactinIBA 10/2017
1	ONC206IBA 10/2017
1	TNF-Related Apoptosis-Inducing LigandIBA 01/2017
1	LigandsIBA 11/2016

Therapy/Procedure

4	Therapeutics 10/2019 - 11/2016
1	Radiotherapy 04/2019
1	Oral Administration 01/2019